BACKGROUND: Stereotactic body radiation therapy (SBRT) has high efficacy for early-stage hepatocellular carcinoma (HCC) and is an accepted alternative to radiofrequency ablation (RFA). However, SBRT for HCC may cause subacute liver injury leading to negative clinical outcomes. In this study, we compared changes of liver function and prognosis after SBRT or RFA in patients with single, small HCC by using a propensity-score matching analysis. METHODS: We reviewed medical records of 140 patients with single ≤3 cm HCC treated with SBRT or RFA at Kurashiki Central Hospital between January 2014 and February 2019. Changes of albumin-bilirubin (ALBI) score, local recurrence, and overall survival were compared between the propensity-score matched groups (31 patients treated with SBRT and 62 treated with RFA). RESULTS: The ALBI score increased modestly but significantly after SBRT, while it was unchanged in the RFA group; the intergroup difference was statistically significant (P=0.004). No local recurrence was identified in the SBRT group, whereas the cumulative recurrence incidence was 9.7% in the RFA group (P=0.023). Overall survival was not significantly different between the two groups (hazard ratio: 1.32, 95% confidence interval: 0.60-2.89, P=0.401). CONCLUSIONS: SBRT had modestly negative impact on liver function but with appraisable local control of HCC. Our findings should contribute to the selection of this modality for treatment of single, small HCC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Stereotactic body radiation therapy (SBRT) has high efficacy for early-stage hepatocellular carcinoma (HCC) and is an accepted alternative to radiofrequency ablation (RFA). However, SBRT for HCC may cause subacute liver injury leading to negative clinical outcomes. In this study, we compared changes of liver function and prognosis after SBRT or RFA in patients with single, small HCC by using a propensity-score matching analysis. METHODS: We reviewed medical records of 140 patients with single ≤3 cm HCC treated with SBRT or RFA at Kurashiki Central Hospital between January 2014 and February 2019. Changes of albumin-bilirubin (ALBI) score, local recurrence, and overall survival were compared between the propensity-score matched groups (31 patients treated with SBRT and 62 treated with RFA). RESULTS: The ALBI score increased modestly but significantly after SBRT, while it was unchanged in the RFA group; the intergroup difference was statistically significant (P=0.004). No local recurrence was identified in the SBRT group, whereas the cumulative recurrence incidence was 9.7% in the RFA group (P=0.023). Overall survival was not significantly different between the two groups (hazard ratio: 1.32, 95% confidence interval: 0.60-2.89, P=0.401). CONCLUSIONS: SBRT had modestly negative impact on liver function but with appraisable local control of HCC. Our findings should contribute to the selection of this modality for treatment of single, small HCC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Devalkumar J Rajyaguru; Andrew J Borgert; Angela L Smith; Reggie M Thomes; Patrick D Conway; Thorvardur R Halfdanarson; Mark J Truty; A Nicholas Kurup; Ronald S Go Journal: J Clin Oncol Date: 2018-01-12 Impact factor: 44.544
Authors: Tracy R Price; Susan M Perkins; Kumar Sandrasegaran; Mark A Henderson; Mary A Maluccio; Jennifer E Zook; A Joseph Tector; Rodrigo M Vianna; Peter A S Johnstone; Higinia R Cardenes Journal: Cancer Date: 2011-10-24 Impact factor: 6.860
Authors: Jin Woo Choi; Jeong Min Lee; Dong Ho Lee; Jeong-Hee Yoon; Kyung-Suk Suh; Jung-Hwan Yoon; Yoon Jun Kim; Jeong-Hoon Lee; Su Jong Yu; Joon Koo Han Journal: PLoS One Date: 2016-08-30 Impact factor: 3.240